HXB Stock Chart & Stats
€6.09
€0.00(0.00%)
At close: 4:00 PM EDT
€6.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€6.09 - €6.09
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.54M
Enterprise Value-€1.18
Total Cash (Recent Filing)€9.96M
Total Debt (Recent Filing)€3.92M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.84
Shares Outstanding39,178,856
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.73Price Target Upside-38.73% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.68
Revenue Forecast (FY)€52.87K
Bulls Say, Bears Say
Bulls Say
Clinical And Manufacturing ReadinessExpanding manufacturing capability for Ampligen supports execution of ongoing and future clinical studies, including a potential pancreatic cancer Phase 3 trial. This improves supply readiness and may reduce operational barriers as AIM seeks to advance its lead candidate through regulatory development.
Reduced Current LeverageCurrent debt is modest relative to equity, reducing the immediate burden of interest and principal obligations. That provides some financial flexibility compared with a heavily debt-funded structure, although the company still needs to address losses and ongoing financing requirements.
Multi-indication Development PotentialAmpligen’s development across multiple therapeutic and antiviral applications gives AIM several potential paths to create value from its core asset. A broader indication set can diversify clinical opportunities and preserve strategic flexibility if progress differs across programs.
Bears Say
Minimal Revenue And Deep LossesA very small revenue base alongside substantial gross, operating, and net losses shows that AIM has not yet established commercial-scale economics. Continued dependence on clinical development means profitability is unlikely to provide near-term internal funding for expansion.
Persistent Cash BurnNegative operating and free cash flow indicate that AIM’s activities consume substantial cash rather than generate funds for reinvestment. Persistent burn increases reliance on external financing and can constrain the company’s ability to sustain studies, manufacturing, and other development priorities.
Equity Dilution For Debt ReductionUsing common stock to extinguish debt reduces obligations but increases the share count and transfers part of the financing burden to existing holders. Repeated equity-based balance-sheet management signals that AIM may continue relying on dilution while cash generation remains weak.
AIM ImmunoTech News
HXB FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest stock price was €6.09 and its highest was €6.09 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is €6.54M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Aug 17, 2027 which is in 322 days.
How were AIM ImmunoTech’s earnings last quarter?
AIM ImmunoTech released its earnings results on Aug 10, 2026. The company reported -€0.371 earnings per share for the quarter, missing the consensus estimate of -€0.147 by -€0.224.
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Overvalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech pays a N/A dividend of €0.235 which represents an annual dividend yield of N/A. See more information on AIM ImmunoTech dividends here
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 39,178,856 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
AIM ImmunoTech reported an EPS of -€0.371 in its last earnings report, missing expectations of -€0.147. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in DE:HXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
HXB Stock 12 Month Forecast
Average Price Target
€3.73
▼(-38.73% Downside)